Objectives of chemotherapy for unresectable liver metastases: Best response or resection?

European Journal of Cancer, Supplement

Volumn 5, Issue 5, 2007, Pages 317-321

  Sobrero, Alberto ^a   De Cian, Franco ^b   Andretta, Valeria ^a   Pessino, Anna ^a  

^a Medical Oncology Unit   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; COLORECTAL CANCER; HUMAN; INOPERABLE CANCER; LIVER METASTASIS; LIVER RESECTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 35548966218     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(07)70059-9     Document Type: Article

References (27)

1. Bismuth H., Adam R., Levi F., et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224 4 (1996) 509-520 discussion 520-2.
2. Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 14 suppl 2 (2003) ii13-ii16
3. Giacchetti S., Itzhaki M., Gruia G., et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10 6 (1999) 663-669
4. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 2 (2004) 229-237
5. Folprecht G., Grothey A., Alberts S., et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16 8 (2005) 1311-1319
6. Cervantes A., Casado E., Van Cutsem E., et al. Cetuximab plus oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) for the epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC) in the first-line setting: a phase II study. Eur J Cancer Suppl 3 2 (2005) 181 abstract 642.
7. Fisher G., Kuo T., Cho D., et al. A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. J Clin Oncol 22 14S (2004) abstract 3514.
8. Folprecht G., Lutz M., Schoffski P., et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17 3 (2006) 450-456
9. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 23 (2004) 2335-2342
10. Kopetz S., Abbruzzese J., Eng C., et al. Preliminary results from a phase II study of infusional 5-FU, leucovorin and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). J Clin Oncol 24 18S (2006) abstract 3579.
11. Peeters M., Raoul J.-L., Van Laetham J.-L., et al. Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer. Eur J Cancer Suppl 3 2 (2005) 188 abstract 664.
12. Abad A., Anton A., Massuti B., et al. Resectability of liver metastases (LM) in patients with advanced colorectal cancer (ACRC) after treatment with the combination of oxaliplatin (OXA), irinotecan (IRI) and 5-FU: Final results of a phase II study. J Clin Oncol 23 16S (2005) 275 abstract 3618.
13. Falcone A, Masi G, Murr R, et al. Biweekly irinotecan, oxaliplatin, and infusional 5-FU/LV (FOLFOXIRI) versus FOLFIRI as first-line treatment of metastatic CRC (MCRC). ASCO Gastrointestinal Cancers Symposium www.asco.org 2006, abstract 227.
14. Quenet F., Nordlinger B., Rivoire M., et al. Resection of previously unresectable liver metastases from colorectal cancer after chemotherapy with CPT-11/L-OHP/LV5FU (Folfirinox): A prospective phase II trial. Proc Am Soc Clin Oncol 23 (2004) abstract 3613.
15. Seium Y., Stupp R., Ruhstaller T., et al. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. Ann Oncol 16 5 (2005) 762-766
16. Van Cutsem E., Nordlinger B., Adam R., et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 42 (2006) 2212-2221
17. Elias D., Sideris L., Pocard M., et al. Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol 11 3 (2004) 274-280
18. Guyot F., Faivre J., Manfredi S., et al. Time trends in the treatment and survival of recurrences from colorectal cancer. Ann Oncol 16 (2005) 756-761
19. Poston G., Adam R., and Vauthey J. Downstaging or downsizing: time for a new staging system in advanced colorectal cancer?. J Clin Oncol 24 (2006) 2702-2706
20. Adam R., Delvart V., Valenau A., et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240 (2004) 644-657
21. Masi G., Cupini S., Marcucci L., et al. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg 13 (2006) 58-65
22. Giacchetti S., Itzhaki M., Gruia G., et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10 (1999) 663-669
23. Adam R. Developing strategies for liver metastases from colorectal cancer. Semin Oncol 34 2 (2007) S7-S11 (Suppl 1)
24. Alberts S., Horvat W., Sternfeld W., et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver- only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 23 (2005) 9243-9249
25. Pozzo C., Basso M., Cassano A., et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 15 (2004) 933-939
26. Fong Y., Fortner J., Sun R., et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 229 (1999) 309-318
27. Benoist S., Brouquet A., Penna C., et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?. J Clin Oncol 24 (2006) 3939-3945